Healthcare >> Analyst Interviews >> November 14, 2011

Product Pipeline & Diversification Are Key In Pharma – Dr. Jon Lecroy, M.d. – Mkm Partners

Dr. Jon LeCroy, M.D., joined MKM Partners in June 2011 as an Analyst covering the biotechnology/specialty pharmaceuticals sector. Dr. LeCroy previously covered the same sector at Hapoalim Securities USA, Inc.; Natixis Bleichroeder LLC; and Goldman Sachs. He ranked number five in this year's The Wall Street Journal Best on the Street poll in biotechnology. Dr. LeCroy holds an MBA from Boston University's Graduate School of Management, an M.D. from the University of South Florida College of Medicine and a B.S. in biology from Wake Forest University. Profile
TWST: What is your coverage in the pharma sector?

Dr. LeCroy: Right now, I cover Pfizer (PFE) and Bristol-Myers (BMY). I have covered all the U.S. names in the past, which really is only Pfizer,